Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Plus Chemotherapy in First-line HER2+ NSCLC
NCT04706949Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04706949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706949.